170 related articles for article (PubMed ID: 23763798)
21. Gemcitabine and vinorelbine as a salvage regimen for relapse in Hodgkin lymphoma after autologous hematopoietic stem cell transplantation.
Ozkaynak MF; Jayabose S
Pediatr Hematol Oncol; 2004 Mar; 21(2):107-13. PubMed ID: 15160509
[TBL] [Abstract][Full Text] [Related]
22. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.
O'Connor OA; Lue JK; Sawas A; Amengual JE; Deng C; Kalac M; Falchi L; Marchi E; Turenne I; Lichtenstein R; Rojas C; Francescone M; Schwartz L; Cheng B; Savage KJ; Villa D; Crump M; Prica A; Kukreti V; Cremers S; Connors JM; Kuruvilla J
Lancet Oncol; 2018 Feb; 19(2):257-266. PubMed ID: 29276022
[TBL] [Abstract][Full Text] [Related]
23. Ifosfamide and vinorelbine is an effective reinduction regimen in children with refractory/relapsed Hodgkin lymphoma, AHOD00P1: a children's oncology group report.
Trippett TM; Schwartz CL; Guillerman RP; Gamis AS; Gardner S; Hogan S; London WB; Chen L; de Alarcon P
Pediatr Blood Cancer; 2015 Jan; 62(1):60-4. PubMed ID: 25308760
[TBL] [Abstract][Full Text] [Related]
24. Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism.
Blum KA; Jung SH; Johnson JL; Lin TS; Hsi ED; Lucas DM; Byrd JC; Cheson BD; Bartlett NL;
Ann Oncol; 2010 Nov; 21(11):2246-2254. PubMed ID: 20423913
[TBL] [Abstract][Full Text] [Related]
25. Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma.
Moskowitz AJ; Shah G; Schöder H; Ganesan N; Drill E; Hancock H; Davey T; Perez L; Ryu S; Sohail S; Santarosa A; Galasso N; Neuman R; Liotta B; Blouin W; Kumar A; Lahoud O; Batlevi CL; Hamlin P; Straus DJ; Rodriguez-Rivera I; Owens C; Caron P; Intlekofer AM; Hamilton A; Horwitz SM; Falchi L; Joffe E; Johnson W; Lee C; Palomba ML; Noy A; Matasar MJ; Pongas G; Salles G; Vardhana S; Sanin BW; von Keudell G; Yahalom J; Dogan A; Zelenetz AD; Moskowitz CH
J Clin Oncol; 2021 Oct; 39(28):3109-3117. PubMed ID: 34170745
[TBL] [Abstract][Full Text] [Related]
26. Phase II study of vinorelbine and gemcitabine for inoperable stage IIIB-IV non-small-cell lung cancer.
Isokangas OP; Knuuttila A; Halme M; Mäntylä M; Lindström I; Nikkanen V; Viren M; Joensuu H; Mattson K
Ann Oncol; 1999 Sep; 10(9):1059-63. PubMed ID: 10572603
[TBL] [Abstract][Full Text] [Related]
27. Bendamustine salvage for the treatment of relapsed Hodgkin's lymphoma after allogeneic bone marrow transplantation.
Mian M; Farsad M; Pescosta N; Casini M; Cavattoni IM; Deola S; Cortelazzo S
Ann Hematol; 2013 Jan; 92(1):121-3. PubMed ID: 22820997
[No Abstract] [Full Text] [Related]
28. Rituximab in combination with vinorelbine/gemcitabine chemotherapy in patients with primary refractory or early relapsed T cell rich B cell lymphoma. A pilot study.
Xiros N; Economopoulos T; Valsami S; Rontogianni D; Fountzilas G; Raptis S
Leuk Res; 2003 Dec; 27(12):1097-9. PubMed ID: 12921946
[TBL] [Abstract][Full Text] [Related]
29. Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non-small-cell lung cancer: from the German and Swiss Lung Cancer Study Group.
Laack E; Dickgreber N; Müller T; Knuth A; Benk J; Lorenz C; Gieseler F; Dürk H; Engel-Riedel W; Dalhoff K; Kortsik C; Graeven U; Burk M; Dierlamm T; Welte T; Burkholder I; Edler L; Hossfeld DK;
J Clin Oncol; 2004 Jun; 22(12):2348-56. PubMed ID: 15197195
[TBL] [Abstract][Full Text] [Related]
30. Response rates, long term outcomes and toxicity profile of gemcitabine and vinorelbine based outpatient chemotherapy regimen in primary progressive and relapsed childhood Hodgkin lymphoma.
Jan MRU; Saeed H; Abubakar M; Wali RM
Leuk Lymphoma; 2020 Dec; 61(14):3369-3377. PubMed ID: 32924702
[TBL] [Abstract][Full Text] [Related]
31. [Rituximab combined with second line regimens for treatment of seven relapsed and refractory Hodgkin lymphoma patients].
Liu H; Li H; Xiong W; Yi S; Zou D; Qiu L
Zhonghua Xue Ye Xue Za Zhi; 2015 Jul; 36(7):578-82. PubMed ID: 26304082
[TBL] [Abstract][Full Text] [Related]
32. The effect of gemcitabine, dexamethasone, and cisplatin chemotherapy in relapsed/refractory NHL and HL patients: A single center experience.
Batgi H; Merdin A; Dal MS; Kızıl Çakar M; Yıldız J; Başçı S; Uncu Ulu B; Yiğenoğlu TN; Darçın T; Şahin D; Bakırtaş M; Tetik A; İskender D; Altuntaş F
J Oncol Pharm Pract; 2020 Dec; 26(8):1857-1863. PubMed ID: 32098553
[TBL] [Abstract][Full Text] [Related]
33. Gemcitabine plus vinorelbine as an effective salvage chemotherapeutic regimen in advanced Hodgkin lymphoma.
Chen JH; Chang PY; Yao NS
Hematol Oncol Stem Cell Ther; 2009; 2(2):371-2. PubMed ID: 20118065
[No Abstract] [Full Text] [Related]
34. Low fixed dose pembrolizumab with gemcitabine, vinorelbine, liposomal doxorubicin (Pembro100 -GVD) as an effective salvage regimen in relapsed refractory classical hodgkin's lymphoma and primary mediastinal B cell lymphoma.
Panda T; Rainchwar S; Halder R; Singh R; Bhurani D; Agrawal N
Ann Hematol; 2024 Jan; 103(1):347-349. PubMed ID: 37740065
[No Abstract] [Full Text] [Related]
35. Gemcitabine-Based Treatment in Poor-Prognosis Patients with Relapsed and Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma--a Multicenter Polish Experience.
Rybka J; Jurczak W; Giza A; Paszkiewicz-Kozik E; Kumiega B; Drozd-Sokołowska J; Butrym A; Kuliczkowski K; Wróbel T
Adv Clin Exp Med; 2015; 24(5):783-9. PubMed ID: 26768628
[TBL] [Abstract][Full Text] [Related]
36. Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease.
Josting A; Rudolph C; Reiser M; Mapara M; Sieber M; Kirchner HH; Dörken B; Hossfeld DK; Diehl V; Engert A;
Ann Oncol; 2002 Oct; 13(10):1628-35. PubMed ID: 12377653
[TBL] [Abstract][Full Text] [Related]
37. Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group.
Baetz T; Belch A; Couban S; Imrie K; Yau J; Myers R; Ding K; Paul N; Shepherd L; Iglesias J; Meyer R; Crump M
Ann Oncol; 2003 Dec; 14(12):1762-7. PubMed ID: 14630682
[TBL] [Abstract][Full Text] [Related]
38. A multicenter study of gemcitabine-containing regimen in relapsed or refractory Hodgkin's lymphoma patients.
Validire P; Fermé C; Brice P; Diviné M; Gabarre J; Bouabdallah K; Fitoussi O; Chaoui D; Pacquement H; Soussain C; Carde P; Salhi R; Zanni M; Decaudin D
Anticancer Drugs; 2008 Mar; 19(3):309-15. PubMed ID: 18510178
[TBL] [Abstract][Full Text] [Related]
39. Gemcitabine, etoposide, cisplatin, and dexamethasone in patients with refractory or relapsed non-Hodgkin's lymphoma.
Kim KH; Joo YD; Sohn CH; Shin HJ; Chung JS; Cho GJ; Shin SH; Kim YS; Lee WS
Korean J Intern Med; 2009 Mar; 24(1):37-42. PubMed ID: 19270480
[TBL] [Abstract][Full Text] [Related]
40. The combination of gemcitabine and vinorelbine is an active regimen as second-line therapy in patients with metastatic breast cancer pretreated with taxanes and/or anthracyclines: a phase I-II study.
Morabito A; Filippelli G; Palmeri S; Cascinu S; Ferraù F; Zagonel V; Gattuso D; Catalano V; Capaccetti B; Franciosi V; Accurso V; Scinto F; Gasparini G
Breast Cancer Res Treat; 2003 Mar; 78(1):29-36. PubMed ID: 12611454
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
